Literature DB >> 9368613

MUC1 peptide epitopes associated with five different H-2 class I molecules.

V Apostolopoulos1, J S Haurum, I F McKenzie.   

Abstract

We have previously described the induction of murine CD8+ major histocompatibility complex (MHC) class I-restricted cytotoxic T cells (CTL) recognizing the 20-amino acid repeat region of the human mucin 1 (MUC1) variable number of tandem repeats region (VNTR), a mucin greatly increased in expression in breast cancer and proposed as a target for immunotherapy. In that study, CTL could detect MUC1 peptides associated with the MHC of all nine strains examined, and we now report the different epitopes presented by five different MHC class I molecules. The epitopes were defined in CTL assays using peptide-pulsed phytohemagglutinin blasts or MHC class I-transfected L cells as targets; in addition, peptide binding assays and T cell proliferation studies were performed. Within the 20-amino acid VNTR, nine potential epitopes could be defined. The epitopes for the four MHC class I molecules [Kb (three epitopes), Dd, Ld and Kk] were closely related, all containing the amino acids PDTRPAP. For Db, three epitopes were identified, all containing APGSTAP. Most of the epitopes did not contain a consensus motif for the particular MHC class I allele, and bound with low 'affinity', compared with known high-affinity peptides. CD8+ T cell proliferation also occurred to the same MHC class I-presented epitopes. Finally, when conventional anchor residues were introduced into the peptides, peptide binding increased, whereas CTL recognition was either retained (Kb) or lost (Db) depending on the epitope.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9368613     DOI: 10.1002/eji.1830271017

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

1.  Towards immunotherapy of pancreatic cancer.

Authors:  I F McKenzie; V Apostolopoulos
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

2.  A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor.

Authors:  Vasso Apostolopoulos; Elizabeth Yuriev; Paul A Ramsland; Jodie Halton; Carla Osinski; Wenjun Li; Magdalena Plebanski; Hans Paulsen; Ian F C McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

3.  Delivery of foreign cytotoxic T lymphocyte epitopes to tumor tissues for effective antitumor immunotherapy against pre-established solid tumors in mice.

Authors:  Herbert W Kavunja; Shuyao Lang; Suttipun Sungsuwan; Zhaojun Yin; Xuefei Huang
Journal:  Cancer Immunol Immunother       Date:  2016-12-23       Impact factor: 6.968

Review 4.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

5.  Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.

Authors:  J Gong; V Apostolopoulos; D Chen; H Chen; S Koido; S J Gendler; I F McKenzie; D Kufe
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

6.  Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.

Authors:  Eliada Lazoura; Jodie Lodding; William Farrugia; Paul A Ramsland; James Stevens; Ian A Wilson; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

7.  Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.

Authors:  Nitin T Supekar; Vani Lakshminarayanan; Chantelle J Capicciotti; Anju Sirohiwal; Cathy S Madsen; Margreet A Wolfert; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal:  Chembiochem       Date:  2017-11-30       Impact factor: 3.164

8.  Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells.

Authors:  Kuo-Ching Sheng; Dodie S Pouniotis; Mark D Wright; Choon Kit Tang; Eliada Lazoura; Geoffrey A Pietersz; Vasso Apostolopoulos
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

9.  Homology modeling and molecular dynamics simulations of MUC1-9/H-2K(b) complex suggest novel binding interactions.

Authors:  Athanassios Stavrakoudis; Ioannis G Tsoulos; Katalin Uray; Ferenc Hudecz; Vasso Apostolopoulos
Journal:  J Mol Model       Date:  2010-11-16       Impact factor: 1.810

10.  MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.

Authors:  P Mukherjee; L B Pathangey; J B Bradley; T L Tinder; G D Basu; E T Akporiaye; S J Gendler
Journal:  Vaccine       Date:  2006-11-16       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.